SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.
More SynBiotic content >Investment summary
SynBiotic has extended its lead in the European hemp and cannabis sector and is continuing to build a cannabis ‘ecosystem’, encompassing cultivation, production and trade. Based on preliminary figures, SynBiotic has delivered pro forma sales of €15m for FY21, in line with management guidance. The company has now added a target of becoming profitable as of FY23. Full consolidated financial statements will be presented at the AGM, planned in Q4.
Content on SynBiotic
SynBiotic – Management update – on track
Consumer
|
research Update
|
9 August 2022
SynBiotic – Further acquisitions
Consumer
|
research Update
|
6 December 2021
SynBiotic – Building a cannabis platform
Consumer
|
research QuickView
|
1 November 2021
Sector |
|---|
|
Consumer
Access more Consumer content
|
Share price graph
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Lars Müller | CEO |
| Alexander Guercueyan | CFO |